Literature DB >> 11829097

Airway responsiveness and peak flow variability in the diagnosis of asthma for epidemiological studies.

S A Lewis1, S T Weiss, J R Britton.   

Abstract

Airway responsiveness and variability in peak expiratory flow (PEF) are widely used as objective diagnostic measures of asthma, but it is not clear how these variables should be calculated or adjusted to obtain the highest diagnostic validity for physician-diagnosed asthma in the community. Data from a community-based sample of 1,513 adults has been used. Airway responsiveness to methacholine and 7-day PEF data were obtained in 1991, asthma and respiratory symptoms were diagnosed by questionnaires in 1991 and 1999. Airway responsiveness was expressed as the provocative dose causing a 20% fall in forced expiratory volume in one second (PD20), two-point and least-squares regression slopes. PEF variability was expressed as daily amplitude, weekly standard deviation and mean of the two lowest readings. Continuous measures were adjusted for measures of baseline airway calibre by linear regression. Measures of airway responsiveness had greater sensitivity for specificity for self-reported diagnosed asthma than expressions of PEF variability, before and after adjustment for airway calibre. Diagnostic validity was substantially better in adults aged <50 yrs; PD20 provided the best sensitivity for specificity (61% for 95% at 8.3 micromol). In those aged > or =50 yrs, no measure was closely related to diagnosed asthma. In younger age groups, provocative dose causing a 20% fall in forced expiratory volume in one second provides a valuable objective measure of asthma for epidemiological studies, but is unable to distinguish between asthma and chronic obstructive pulmonary disease in older people.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11829097     DOI: 10.1183/09031936.01.00211801

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Association between air pollution exposure and exhaled nitric oxide in an elderly population.

Authors:  G Adamkiewicz; S Ebelt; M Syring; J Slater; F E Speizer; J Schwartz; H Suh; D R Gold
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

2.  Monitoring the temporal changes of respiratory resistance: a novel test for the management of asthma.

Authors:  Carlo Gulotta; Béla Suki; Vito Brusasco; Riccardo Pellegrino; Alessandro Gobbi; Antonio Pedotti; Raffaele L Dellacà
Journal:  Am J Respir Crit Care Med       Date:  2012-06-15       Impact factor: 21.405

Review 3.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  The American Thoracic Society's spirometric criteria alone is inadequate in asthma diagnosis.

Authors:  John A Gjevre; Thomas S Hurst; Regina M Taylor-Gjevre; Donald W Cockcroft
Journal:  Can Respir J       Date:  2006 Nov-Dec       Impact factor: 2.409

Review 5.  Dietary sodium manipulation and asthma.

Authors:  Zara Pogson; Tricia McKeever
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

6.  Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD).

Authors:  Emily S Wan; Dawn L DeMeo; Craig P Hersh; Steven D Shapiro; Richard A Rosiello; Susan R Sama; Anne L Fuhlbrigge; Marilyn G Foreman; Edwin K Silverman
Journal:  Respir Med       Date:  2010-12-10       Impact factor: 3.415

7.  Reference values for methacholine reactivity (SAPALDIA study).

Authors:  Pierre-Yves Jayet; Christian Schindler; Nino Künzli; Jean-Pierre Zellweger; Otto Brändli; André Paul Perruchoud; Roland Keller; Joel Schwartz; Ursula Ackermann-Liebrich; Philippe Leuenberger
Journal:  Respir Res       Date:  2005-11-04

8.  Assessing the exacerbations risk of influenza-associated chronic occupational asthma.

Authors:  Chung-Min Liao; Nan-Hung Hsieh; Chia-Pin Chio; Szu-Chieh Chen
Journal:  Risk Anal       Date:  2010-04-08       Impact factor: 4.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.